Trial · NCT00106106
Acamprosate to Reduce Symptoms of Alcohol Withdrawal
NCT00106106, Phase 2, Completed, National Institutes of Health Clinical Center (CC); results first posted 2012-01-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acamprosate to Reduce Symptoms of Alcohol Withdrawal. Trials, record NCT00106106. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00106106
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acamprosate to Reduce Symptoms of Alcohol Withdrawal
- NCT number
- NCT00106106
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 56 participants, actual
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- Conditions
- Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
- Interventions
- NMR-spectroscopy, Oral acamprosate
- First posted
- 2005-03-21
- Last updated
- 2012-01-12
- Results first posted
- 2012-01-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 | Day 4 | The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. |
| Primary | Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25 | Day 25 | The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 | Day 4 | The analysis of participants was per protocol, i.e., all subjects who completed two MRS scans(Day 4 and Day 25) and for whom there were two measures of the glutamate/creatine ratio | Ratio of glutamate to creatine | MEAN |
| PRIMARY | Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25 | Day 25 | Ratio of glutamate to creatine | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 | Placebo | 1.256772 | Standard Error 0.038924 | Ratio of glutamate to creatine | |
| Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 | Acamprosate | 1.294178 | Standard Error 0.043249 | Ratio of glutamate to creatine | |
| Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25 | Placebo | 1.350375 | Standard Error 0.044497 | Ratio of glutamate to creatine | |
| Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25 | Acamprosate | 1.166667 | Standard Error 0.049441 | Ratio of glutamate to creatine |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 26 | |
| Overall Study | STARTED | Acamprosate | 23 | |
| Overall Study | Completed Both MRS Scans | Placebo | 18 | |
| Overall Study | Completed Both MRS Scans | Acamprosate | 15 | |
| Overall Study | COMPLETED | Placebo | 22 | |
| Overall Study | COMPLETED | Acamprosate | 19 | |
| Overall Study | NOT COMPLETED | Placebo | 4 | |
| Overall Study | NOT COMPLETED | Acamprosate | 4 |
Source ClinicalTrials.gov
Adverse events42
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abnormal Dreaming | Nervous system disorders | Placebo | 11 | 22 | |
| other | Abnormal Dreaming | Nervous system disorders | Acamprosate | 11 | 19 | |
| other | Anxiety | Nervous system disorders | Placebo | 9 | 22 | |
| other | Anxiety | Nervous system disorders | Acamprosate | 12 | 19 | |
| other | Decreased interest in sex | Nervous system disorders | Placebo | 6 | 22 | |
| other | Decreased interest in sex | Nervous system disorders | Acamprosate | 6 | 19 | |
| other | Diarrhea | Gastrointestinal disorders | Placebo | 3 | 22 | |
| other | Diarrhea | Gastrointestinal disorders | Acamprosate | 6 | 19 | |
| other | Dizziness | Nervous system disorders | Placebo | 5 | 22 | |
| other | Dizziness | Nervous system disorders | Acamprosate | 6 | 19 |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Acamprosate | ||
| Total, other adverse events | Placebo | 20 | 22 |
| Total, other adverse events | Acamprosate | 18 | 19 |
| Total, serious adverse events | Placebo | 0 | 26 |
| Total, serious adverse events | Acamprosate | 1 | 23 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Acamprosate vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00106106
GET https://conductscience.org/api/trials/v1/NCT00106106/events?page=2